Mark Bernstein

Summary

Country: Canada

Publications

  1. ncbi Ewing's sarcoma family of tumors: current management
    Mark Bernstein
    Service of Hematology Oncology, Ste Justine Hospital, University of Montreal, 3175 Cote Ste Catherine Road, Montreal, Quebec, H3T 1C5, Canada
    Oncologist 11:503-19. 2006
  2. ncbi Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study
    Martin A Champagne
    Hopital Sainte Justine, 3175 Cote Ste Catherine, Montreal, QC, Canada, H3T 1C5
    Blood 104:2655-60. 2004
  3. ncbi Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial
    Allen M Goorin
    Dana Farber Cancer Institute, The Children s Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 20:426-33. 2002
  4. ncbi A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study
    Anne Marie Langevin
    University of Texas Health Science Center, San Antonio, Texas, USA
    Pediatr Blood Cancer 50:577-80. 2008
  5. ncbi Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group
    Torunn I Yock
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 24:3838-43. 2006
  6. ncbi Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a pediatric oncology group phase I study
    Mark L Greenberg
    Hospital for Sick Children, Toronto, Ontario, Canada
    Pediatr Blood Cancer 45:644-8. 2005
  7. ncbi Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study
    Terzah M Horton
    University of Texas Health Science Center, San Antonio, TX, USA
    Clin Cancer Res 11:1884-9. 2005
  8. ncbi A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study
    Loretta Lau
    New Agent and Innovative Therapy Program, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8
    Clin Cancer Res 11:672-7. 2005
  9. ncbi Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015)
    Susan M Blaney
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 22:4804-9. 2004
  10. ncbi Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study
    Victor M Aquino
    University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
    J Clin Oncol 22:1413-9. 2004

Collaborators

Detail Information

Publications16

  1. ncbi Ewing's sarcoma family of tumors: current management
    Mark Bernstein
    Service of Hematology Oncology, Ste Justine Hospital, University of Montreal, 3175 Cote Ste Catherine Road, Montreal, Quebec, H3T 1C5, Canada
    Oncologist 11:503-19. 2006
    ..New approaches include anti-angiogenic therapy, particularly since vascular endothelial growth factor is an apparent downstream target of the ews-fli1 oncogene...
  2. ncbi Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study
    Martin A Champagne
    Hopital Sainte Justine, 3175 Cote Ste Catherine, Montreal, QC, Canada, H3T 1C5
    Blood 104:2655-60. 2004
    ..Doses of 260 and 340 mg/m(2) provide systemic exposures similar to those of adults who are treated with daily doses of 400 and 600 mg, respectively...
  3. ncbi Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial
    Allen M Goorin
    Dana Farber Cancer Institute, The Children s Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 20:426-33. 2002
    ....
  4. ncbi A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study
    Anne Marie Langevin
    University of Texas Health Science Center, San Antonio, Texas, USA
    Pediatr Blood Cancer 50:577-80. 2008
    ....
  5. ncbi Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group
    Torunn I Yock
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 24:3838-43. 2006
    ..We investigated the relationship between the type of local control modality, surgery, radiation (RT) or both (S + RT), and subsequent risk for local failure (LF) in patients with nonmetastatic pelvic Ewing sarcoma treated on INT-0091...
  6. ncbi Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a pediatric oncology group phase I study
    Mark L Greenberg
    Hospital for Sick Children, Toronto, Ontario, Canada
    Pediatr Blood Cancer 45:644-8. 2005
    ..Based on their imaging characteristics, we postulated that inhibition of P-glycoprotein (P-gp) associated with endothelial cells of the blood-brain barrier might enhance penetration of xenobiotic antineoplastics...
  7. ncbi Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study
    Terzah M Horton
    University of Texas Health Science Center, San Antonio, TX, USA
    Clin Cancer Res 11:1884-9. 2005
    ..To evaluate the toxicity, antileukemic activity, and pharmacology of raltitrexed administered weekly for 3 weeks to patients with refractory or recurrent leukemia...
  8. ncbi A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study
    Loretta Lau
    New Agent and Innovative Therapy Program, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8
    Clin Cancer Res 11:672-7. 2005
    ..CONCLUSION: ET-743 is safe. The phase II recommended dose of ET-743 administered as a 3-hour i.v. infusion following premedication with dexamethasone is 1,100 microg/m(2)...
  9. ncbi Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015)
    Susan M Blaney
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 22:4804-9. 2004
    ..To determine the maximum-tolerated dose, dose-limiting toxicity (DLT), and pharmacodynamics of the proteasome inhibitor bortezomib (formerly PS-341) in children with recurrent or refractory solid tumors...
  10. ncbi Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study
    Victor M Aquino
    University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
    J Clin Oncol 22:1413-9. 2004
    ..To determine the dose limiting toxicity (DLT), maximum-tolerated dose (MTD), and pharmacokinetic profile of tirapazamine (Sanofi Synthelabo Research, Malvern, PA) combined with cyclophosphamide in children with recurrent solid tumors...
  11. ncbi Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by phenylbutyrate on L1210 leukemic cells
    Maryse Lemaire
    , , , , , , , Canada
    Leuk Lymphoma 45:147-54. 2004
    ..We also observed an enhancement of the antineoplastic activity of this combination in mice with L1210 leukemia. These data provide a rationale to investigate 5-AZA-CdR and PB in patients with advanced leukemia...
  12. ncbi Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary
    Richard Gorlick
    Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 9:5442-53. 2003
    ..This report summarizes the information presented and discussed by the meeting participants...
  13. ncbi Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project
    Edward R Laws
    Department of Neurological Surgery, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    J Neurosurg 99:467-73. 2003
    ..Attempts were made to reduce the impact of selection bias by repeating the data analysis after omitting patients with major negative prognostic factors...
  14. ncbi Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples
    Rui Yang
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 9:837-44. 2003
    ..Additional studies are under way to determine the clinical significance of these sequence alterations and their effect on methotrexate transport and resistance...
  15. ncbi Influence of phenytoin on the disposition of irinotecan: a case report
    Daryl J Murry
    Texas Children's Cancer Center/Baylor College of Medicine, Houston, USA
    J Pediatr Hematol Oncol 24:130-3. 2002
    ..Further detailed pharmacokinetic studies of irinotecan in patients receiving concomitant therapy with enzyme-inducing anticonvulsants are required so that rational dosing recommendations can be provided for this patient population...
  16. ncbi Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study
    Denise M Adams
    Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA
    Pediatr Blood Cancer 50:549-53. 2008
    ....